Founded in 2001, Spring Bioscience was acquired by Ventana Medical Systems who is now a part of the Roche Group. Through our role as a leading antibody development center for Roche, Spring Bioscience is well-positioned to deliver a focused product portfolio to the research market representing the highest value targets for the future diagnosis and prognosis of cancer.

Spring’s products are optimized to help you deliver consistent and high quality results in your laboratory. Our in house rabbit monoclonal technology improves upon traditional hybridoma approaches, allowing us to accelerate the delivery of a broader menu of highly specific and sensitive monoclonal antibodies (SP clones) to the research market. Having developed the SP1 clone, the current gold standard Estrogen Receptor (ER) marker, SP clones continue to emerge as best-in-class cancer markers for your immunohistochemistry (IHC) research.

Spring’s antibody technologies include rabbit monoclonal (SP clones), mouse monoclonal (SPM clones) and rabbit polyclonal. We offer these in four configurations, validated in multiple species, and often optimized for not just IHC but other applications including Western Blot. In addition to our line of antibodies we also sell a complete line of complementary IHC reagents and detection systems as well as an Antibody Microarray to assist in early stage research studies.